US EditionOvercoming Resistance Remains a Challenge in Targeting KRAS - ILCN.org (ILCN/WCLC)
Summary by ILCN.org (ILCN/WCLC)
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Overcoming Resistance Remains a Challenge in Targeting KRAS - ILCN.org (ILCN/WCLC)
Alice Shaw, MD, PhD For several decades, RAS has been considered a potent oncogenic driver; however, until the development of KRAS G12C inhibitors, it was deemed “undruggable.” “This early success with G12C inhibitors, along with additional key insights into targeting RAS, has fueled this explosion and drug discovery, with numerous new RAS inhibitors now in preclinical and clinical development,” said Alice Shaw, MD, PhD, on April 28 during a ses…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
